Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor
NCT ID: NCT04673396
Last Updated: 2020-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
36 participants
INTERVENTIONAL
2020-09-22
2022-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After the end of the experimental drug tolerance and pharmacokinetics study, the safety and pharmacokinetics of single dose administration were compared with that of sodium norcantharidate for injection in the dose range of clinical use.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tolerance test
The design is based on 3+3 dose escalation: three subjects were enrolled in each dose group, administered once a day for 2 weeks, and were observed for 7 days after withdrawal. If dose-limiting toxicity (DLT) was not observed, the dose was incresed to the next dose group. If dose-limiting toxicity (DLT) was found in 2 or more patients in a given dose group, the climbing test was terminated and the dose was reduced by 1 dose. If there were only three subjects, three more subjects were observed, so that the MTD dose group had at least six evaluable subjects.If DLT occurs in 1 patient in a given dose group, 3 more subjects should be added to that dose group. If DLT occurs in 1 or more of these 3 subjects, the climb will be stopped and the dose group will be reduced by 1 dose group. If there are only 3 subjects, 3 more subjects will be observed, so that at least 6 patients in the MTD dose group can be evaluated.
Norcantharidin Lipid Microsphere for Injection
The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.
This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Pharmacokinetic studies
At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
Norcantharidin Lipid Microsphere for Injection
The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.
This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Comparative Study
It is planned to select the 20mg dose of norcantharidin sodium for injection to carry out pharmacokinetic study of 8 cases. The specific research design will be formulated after the tolerance and pharmacokinetic test of norcantharidin lipid microsphere injection is completed.
Norcantharidin Lipid Microsphere for Injection
The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.
This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Sodium Demethylcantharidate Injection
Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Norcantharidin Lipid Microsphere for Injection
The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.
This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Sodium Demethylcantharidate Injection
Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Condition body mass index (BMI) = Weight (kg)/Height 2 (m2), the body mass index is in the range of 18-28 (Including the cut-off value).
3. Patients with locally advanced or metastatic solid tumors that have been clearly diagnosed by histology/cytology, patients whose condition is stable after standard treatment, or those who have failed standard treatment.
4. According to the Eastern Cooperative Oncology Group (ECOG) score of 0 to 2, the estimated survival time is ≥ 3 months.
5. It has sufficient organ and bone marrow functions, defined as follows:
1. Blood routine: white blood cell count (WBC) ≥ 4.0 × 109/L; neutrophil count (NEUT) ≥ 1.5 × 109/L; platelet count (PLT) ≥ 100 × 109/L; hemoglobin concentration ≥ 9.0 g/ dL;
2. Liver function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); for patients with liver cancer or liver metastases, ALT and AST ≤ 5 times ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN;
3. Renal function: blood creatinine (CREA) ≤ 1.5 × ULN;
4. Heart function: LVEF ≥ 50%.
6. Those who have used chemotherapeutics in the past need to stop the drug for more than 4 weeks (mitomycin or nitrosourea, need to stop for more than 6 weeks); have received surgery, molecular targeted therapy, and anti-tumor indications with Chinese medicine Those who need treatment should end at least 4 weeks, and those who have received palliative radiotherapy need more than 4 weeks of treatment.
7. Any toxicity associated with previous anti-tumor treatments must have been restored to ≤ Grade 1 (except for hair loss).
8. During the study period and within 3 months after the end of the administration, subjects with fertility (whether male or female) must receive effective contraceptive measures.
9. With my consent and signed an informed consent form by myself or my legal representative.
Exclusion Criteria
2. There is NCI-CTCAE grade ≥ grade 2 arrhythmia, any grade of atrial fibrillation that is not controlled, or the ECG found at the time of screening that the QT interval (QTc) for two consecutive corrections\> 480ms.
3. Any drug that may prolong the QTc interval or induce torsade de pointes ventricular tachycardia is required within 14 days before the first use of the test drug or during treatment.
4. History of allergic diseases and severe drug allergy.
5. Patients with uncontrolled tumor brain metastases with clinical symptoms.
6. Patients with severe infections (including but not limited to progressive or active infections) (for example, intravenous infusion of antibiotics, antifungal or antiviral drugs, etc.).
7. Patients with severe medical diseases, such as cardiac dysfunction of grade II and above (NYHA standard), ischemic heart disease (such as myocardial infarction or angina), congestive heart failure and other cardiovascular diseases, poorly controlled diabetes (Fasting blood glucose ≥10mmol/L), poorly controlled hypertension (systolic blood pressure\>150mmHg and/or diastolic blood pressure\>100mmHg).
8. Those who have bleeding tendency or are receiving thrombolysis or anticoagulation therapy.
9. Active hepatitis (hepatitis B, hepatitis C) or known HIV infection.
10. Other systemic anti-tumor treatments may be accepted during the study period.
11. A clear history of neurological or mental disorders, including epilepsy or dementia.
12. Have bad habits such as drug and alcohol abuse. Alcoholism refers to drinking behaviors of 4 or more times within about 2 hours. One-time drinking refers to drinking 150ml of wine, 350ml of beer, or 50ml of 80% liquor (or equivalent to the alcohol content).
13. Women during pregnancy or lactation.
14. Those who have received other drug clinical research within 1 month before the study.
15. Other situations where the researcher thinks it is inappropriate to participate in this research.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Nuokangda Pharmaceutical Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yunpeng Liu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital, China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital, China Medical University
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yunpeng Liu, Ph.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DXNCTD2019001
Identifier Type: -
Identifier Source: org_study_id